News

According to researchers at the McGill University Health Centre, about one-third of people worldwide are infected by the bacteria which causes tuberculosis; mycobacterium tuberculosis. “Of the estimated two

Although more than three billion doses of the BCG (bacillus calmette-guerin) vaccine have been administered to fight tuberculosis, the ability of the vaccine to protect adults is very

This provides Antisoma with a seven-year period of market exclusivity for AS1411 upon gaining marketing approval. The compound already has orphan drug designation in the US for the

Rituxan is currently only approved for treatment of patients who have not been helped by other treatments for the disease. The companies are now asking that the drug

Final approval of Teva’s drug is anticipated subsequent to the expiry of patent protection in December 2007. Teva’s generic version of the drug is called Granisetron HCl Injection,

The objective of this partnership is to discover critical scientific insights from large systems biology datasets in real time, and to provide causal models to answer complex therapeutic

2ME2 is currently in clinical trials for cancer, as well as in preclinical development for inflammatory disorders. The patents grant EntreMed intellectual property protection for 2ME2 and its

The combined company has approximately 13.2 million shares issued and outstanding, and based on a $6.30 share price as of August 15, 2005 has a market capitalization of

The study is being conducted at two dosage levels with both dosage levels having the potential for showing safety, preliminary efficacy, and the “bystander effect.” The authorized dosage